# Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

> **NCT07407660** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT07407660
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407660, "Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07407660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*